Canada Pharmaceuticals and Healthcare Report Q1 2011

  • ID: 1503799
  • January 2011
  • Region: Canada
  • 88 Pages
  • Business Monitor International
1 of 4


  • Apotex
  • Biovail (Valeant)
  • GlaxoSmithKline
  • Merck and Co
  • Novartis
  • Pfizer
  • MORE

The Canada Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Canada's pharmaceuticals and healthcare industry.

The Canadian economy is still slowing, and BMI’s Country Risk team is maintaining its belowconsensus projection for 2011. With fiscal stimulus amounting to 2.9% of GDP over the past two fiscal years, we believe government consumption growth will drop from about 4.1% y-o-y in real terms in H110 to 1.5-2.0% by H111. For 2011 as a whole, we expect government consumption growth to come in at 2.0%. Additionally, we are forecasting 2.3% growth in private consumption in 2011, a sharp slowdown from 3.3% in 2010, but still representing a contribution of 1.5 percentage points (pp) to GDP. In BMI’s Pharmaceutical Business Environment Ratings (BERs) for Q111, Canada remains in second place in the expanded regional matrix, trailing the US by almost four points. On a global scale, Canada also ranks second, after the US and above Switzerland, of the 83 markets surveyed globally. Despite READ MORE >

Note: Product cover images may vary from those shown
2 of 4


  • Apotex
  • Biovail (Valeant)
  • GlaxoSmithKline
  • Merck and Co
  • Novartis
  • Pfizer
  • MORE

Executive Summary

SWOT Analysis
Canada Pharmaceuticals And Healthcare Industry SWOT
Canada Political SWOT
Canada Economic SWOT

Pharmaceutical Business Environment Ratings

Table: Americas – Pharmaceuticals Business Environment Ratings, Q111

Canada – Market Summary

OTC Medicines
Intellectual Property Regime
International Collaboration
Pricing Regime
Provincial Pricing Systems
Reimbursement Regime
Recent Pricing and Reimbursement Developments
Industry Developments
Healthcare Sector
International Comparison
Health Expenditure
Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
National Pharmaceuticals Strategy
Pharmaceutical Retail
Research and Development Sector
Medical Devices Industry
Recent Developments in the Medical Devices Industry
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2006-2014
Key Growth Factors – Industry
Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014

Key Growth Factors – Macroeconomic

Table: Canada – Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2006-2014
Patented Product Market Forecast
Table: Patented Drug Sales Indicators 2006-2014
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2006-2014
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2006-2014
Medical Device Market Forecast
Table: Medical Device Sales Indicators 2006-2014
Pharmaceutical Trade Forecasts
Table: Pharmaceutical Imports & Exports Indicators 2006-2014
Other Healthcare Data
Competitive Landscape
Pharmaceutical Industry
Pharmaceutical Re-import Policy
Recent Pharmaceutical Company Developments
Top 20 Pharmaceutical Companies According To Market Capitalisation On The Canadian Stock Exchange

Company Profiles

Domestic Manufacturers

Biovail (Valeant)

Leading Multinational Manufacturers

Merck and Co

Country Snapshot: Canada Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Manufacturing Wages, 2000-2012

BMI Methodology

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components


Note: Product cover images may vary from those shown
3 of 4

- Apotex
- Biovail (Valeant)
- Pfizer
- GlaxoSmithKline
- Sanofi-Aventis
- Merck and Co
- Novartis

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.